Alfacalcidol
- Generic Name
- Alfacalcidol
- Brand Names
- One-alpha
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O2
- CAS Number
- 41294-56-8
- Unique Ingredient Identifier
- URQ2517572
- Background
Alfacalcidol, or 1-alpha-hydroxycholecalciferol or 1-alpha-hydroxyvitamin D3, is a non-endogenous analogue of vitamin D. It plays an essential function in calcium homeostasis and bone metabolism. Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones. The pharmacological actions of alfacalcidol are prolonged than vitamin D because a negative feedback mechanism regulates the final activation step of vitamin D in the kidneys.
Alfacalcidol is available in oral and intravenous formulations. In Canada, it is marketed as ONE-ALPHA, which manages hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in adults with chronic renal failure. In approving European countries, alfacalcidol is also indicated for managing nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic vitamin D resistant rickets and osteomalacia.
- Indication
Alfacalcidol is indicated in adult patients with chronic renal failure for the management of hypocalcemia, secondary hyperparathyroidism, or osteodystrophy.
Alfacalcidol is indicated in the management of nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic vitamin D resistant rickets and osteomalacia.
- Associated Conditions
- Hypocalcemia, Hypophosphatemic Rickets, Nutritional Rickets, Osteodystrophy, Osteomalacia, Rickets, Secondary Hyperparathyroidism (SHPT), Hypophosphatemic osteomalacia
A Study on the Prevention and Treatment of GIOP With Eldecalcitol
- Conditions
- OsteoporosisRheumatoid ArthritisOsteopenia
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 314
- Registration Number
- NCT06385093
- Locations
- 🇨🇳
Beijing Luhe hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Beijing Shunyi hospital, Beijing, Beijing, China
Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients
- Conditions
- Sarcopenia
- Interventions
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 340
- Registration Number
- NCT06272227
- Locations
- 🇰🇷
Division of Endocrinology, Department of internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of
Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma
- Conditions
- Oral MucositisOral Squamous Cell Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Target Recruit Count
- 412
- Registration Number
- NCT06016400
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Alfacalcidol Supplementation on Levator Ani Muscle Strength of Menopausal Pelvic Organ Prolapse Patients
- Conditions
- Pelvic Organ Prolapse
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Universitas Padjadjaran
- Target Recruit Count
- 48
- Registration Number
- NCT05505253
- Locations
- 🇮🇩
Universitas Padjadjaran, Bandung, West Java, Indonesia
Comparison of Serum Calcium Level Between Preoperative Vitamin D and Non-vitamin D Regimen of Total Parathyroidectomy in End-stage Renal Failure Patients in Rajavithi Hospital
- Conditions
- End Stage Renal Disease
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Rajavithi Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04967469
- Locations
- 🇹🇭
Rajavithi Hospital, Bangkok, Thailand
Role of Alphacalcidol Supplement to Reduce Pain and COMP in Geriatric Knee Osteoarthritis Patients
- Conditions
- AgedOsteoarthritis, Knee
- Interventions
- Drug: Sugar pill
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Syarif Hidayatullah State Islamic University Jakarta
- Target Recruit Count
- 146
- Registration Number
- NCT04405960
- Locations
- 🇮🇩
Public Health Service Clinic Reni Jaya, South Tangerang, Banten, Indonesia
Short Term Effect of Vitamin D Supplementation on the Clinical Outcomes in Patients Undergoing Valve Replacement Surgery
- Conditions
- Cardiac Valve Replacement Complication
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 86
- Registration Number
- NCT04085770
- Locations
- 🇪🇬
El-Demerdash Cardiac Academy Hospital, Ain Shams University, Cairo, Egypt
Effect of Alfacalcidol to Respiratory Infection and Immune Response of Indonesian Elderly
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 110
- Registration Number
- NCT03292744
- Locations
- 🇮🇩
Cipto Mangunkusumo National Hospital, Jakarta, Indonesia
Active Vitamin D and Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy
- Conditions
- Minimal Change DiseaseNephrotic Syndrome
- Interventions
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 71
- Registration Number
- NCT03210688
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰Regional Hospital Viborg, Viborg, Denmark
Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan
- Conditions
- Type 2 Diabetic Nephropathy
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2019-10-10
- Target Recruit Count
- 60
- Registration Number
- NCT03147677
- Locations
- 🇨🇳
Hunan Chenzhou NO.1 People's Hospital, Chenzhou, Hunan, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Hunan Yiyang Central Hospital, Yiyang, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.